208183-93-1

Basic information

• Product Name: 2-Propyn-1-ol, 3-(2-fluorophenyl)- (9CI)
• Synonyms: 2-Propyn-1-ol, 3-(2-fluorophenyl)- (9CI);3-(2-Fluorophenyl)-2-propyn-1-ol
• CAS NO: 208183-93-1
• Molecular Formula: C₉H₇FO
• Molecular Weight: 150.1496832
• Product Categories: HALIDE
• Mol File: 208183-93-1.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 244.4±25.0 °C(Predicted)
• Appearance: /
• Density: 1.20±0.1 g/cm3(Predicted)
• PKA: 13.02±0.10(Predicted)
• CAS DataBase Reference: 2-Propyn-1-ol, 3-(2-fluorophenyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Propyn-1-ol, 3-(2-fluorophenyl)- (9CI)(208183-93-1)
• EPA Substance Registry System: 2-Propyn-1-ol, 3-(2-fluorophenyl)- (9CI)(208183-93-1)

Safety Data

• Hazardous Substances Data: 208183-93-1(Hazardous Substances Data)

Upstream product

• 348-52-7 1-Fluoro-2-iodobenzene 
• 107-19-7 propargyl alcohol 

Downstream Products

• 769093-46-1 O-[3-(2-Fluoro-phenyl)-prop-2-ynyl]-hydroxylamine 
• 1020153-63-2 1-(3-bromoprop-1-yn-1-yl)-2-fluorobenzene 
• 406687-57-8 3-(2-fluorophenyl)propiolaldehyde 

Relevant articles and documents

Bi(OTf)3-catalyed One-pot Synthesis of α-Halo-β-amino Ketones and Acyl Aziridines from 3-Aryl Propargyl Alcohols

A Bi(OTf)3-catalyed reaction of 3-aryl propargyl alcohols with sulfonamide and halogen source was firstly investigated, which provided a facile route for the synthesis of a large variety of α-halo-β-amino ketones. The key intermediates, β-amino

Tricyclic Triazoles as σ1Receptor Antagonists for Treating Pain

The synthesis and pharmacological activity of a new series of 5a,7,8,8a-tetrahydro-4H,6H-pyrrolo[3,4-b][1,2,3]triazolo[1,5-d][1,4]oxazine derivatives as potent sigma-1 receptor (σ1R) ligands are reported. A lead optimization program aimed at improving the aqueous solubility of parent racemic nonpolar derivatives led to the identification of several σ1R antagonists with a good absorption, distribution, metabolism, and excretion in vitro profile, no off-target affinities, and characterized by a low basic pKa (around 5) that correlates with high exposure levels in rodents. Two compounds displaying a differential brain-to-plasma ratio distribution profile, 12lR and 12qS, exhibited a good analgesic profile and were selected as preclinical candidates for the treatment of pain.

RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein are a RET inhibitor, a pharmaceutical composition thereof and uses thereof. In particular, provided is a compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Provided is a pharmaceutical composition comprising the compound, and uses of the compound and pharmaceutical composition thereof for the preparation of a medicament, in particular for treatment and prevention of RET-related diseases and conditions, including cancer, irritable bowel syndrome, and/or pain associated with irritable bowel syndrome.